LEXINGTON, Mass.--(BUSINESS WIRE)--Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that it has initiated a Phase 1/2 clinical study of its novel heat shock protein 90 (Hsp90) inhibitor, STA-9090 in hematologic malignancies with a once-a-week dosing schedule. In March, Synta initiated the first Phase 1/2 clinical study of STA-9090 in hematologic malignancies with a twice-weekly dosing schedule. This is the fourth clinical study initiated on STA-9090, a synthetic, small molecule Hsp90 inhibitor with a novel chemical structure that is unrelated to the ansamycin class of Hsp90 inhibitors, including 17-AAG. The other ongoing clinical trials are once-a-week and twice-a-week dosing studies in patients with solid tumors.
